Friday December 29, 1:28 pm ET Merck Closes $1.1 Billion Cash Acquisition of Sirna Therapeutics After Shareholder Vote
WHITEHOUSE STATION, N.J. (AP) -- Drug maker Merck & Co. said Friday it closed its $1.1 billion cash acquisition of the tiny biotech drug developer Sirna Therapeutics Inc. after shareholders approved the deal. Late Thursday, Sirna shareholders voted to approve Merck's $13 per share offer, more than double the company's share price just before the offer was made in late October.
Merck offered to buy the San Francisco-based company for its RNA interference technology, a Nobel Prize-winning technique where genes responsible for diseases are "silenced" by messenger-carrying RNA.
Karen, all your points are taken with interests of all of us who invested and loosing do to a neglegence/intent of the management. We are no bashers. We seek honesty and clearaty from all. I can't devote to a trading stocks and I don't like doing that. My only hope is our, investors, will to get to the bottom of the problem and the Trust seems to me the only force
I rely upon at this uncertain time.